Andy Garner
About Andy Garner
Andy Garner is the Vice President at MOMA Therapeutics, where he has worked since 2019. He has extensive experience in the biotechnology sector, having held key positions at several prominent companies, including Novartis and AstraZeneca.
Current Role at MOMA Therapeutics
Andy Garner serves as Vice President at MOMA Therapeutics, a position he has held since 2019. In this role, he has played a significant part in the development of the company's biology, functional genomics, and new targets groups. Garner has been instrumental in leading the primary drug discovery program, which was essential for the company's value inflection and securing Series B funding.
Previous Experience in the Biopharmaceutical Industry
Prior to his current role, Garner held several key positions in the biopharmaceutical industry. He worked at Third Rock Ventures as a Consultant from 2019 to 2020. Before that, he was a Senior Investigator at Novartis from 2008 to 2012. He also served as Director at ARIAD Pharmaceuticals, Inc. from 2012 to 2014 and as Senior Director at Blueprint Medicines from 2014 to 2019.
Founding Scientist at MOMA Therapeutics
Garner was the founding scientist and the first employee at MOMA Therapeutics. His early contributions were crucial in establishing the company's foundation and strategic direction. He was intimately involved in the successful Series B funding round, which raised $150 million, underscoring his impact on the company's growth.
Educational Background in Biochemistry
Garner earned his PhD in Biochemistry from the University of Dundee, where he studied from 1994 to 1998. This educational background provided him with a strong foundation in the scientific principles that underpin his work in the biopharmaceutical sector.
Career Progression in Pharmaceutical Leadership
Garner's career in the pharmaceutical industry spans over two decades, beginning as a Team Leader at AstraZeneca from 2001 to 2008. His progression through various leadership roles has equipped him with extensive experience in drug discovery and development, contributing to his effectiveness in his current position.